Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2019 | Translating epigenetic therapy to the clinic: rational combinations

Ari Melnick • 24 Feb 2019
ISAL 2019
Acute Myeloid Leukemia Leukemia

Ari Melnick, MD, of Weill Cornell Medical College, New York, NY, discusses the layers of complexity surrounding the epigenome in acute leukemias, which must be better understood in order to more effectively design and utilize epigenetic therapies. He highlights the importance of rational combinations, referencing research using azacitidine with an LSD1 inhibitor on an organoid culture system of primary specimens of acute myeloid leukemia (AML). This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

More from Ari Melnick

3:59
The critical role of SIRT3 in lymphomagenesis
Ari Melnick • 20 Jun 2019
7:18
Precision epigenetic therapy for B-cell lymphoma
Ari Melnick • 20 Jun 2019
2:45
Epigenetic alleles: an emerging concept
Ari Melnick • 25 Feb 2019
8:13
Acute leukemias discussion: what does genomics and epigenomics tell us about patient management?
Ari Melnick et al. • 2 Mar 2018

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals